Perrigo Company PLC (PRGO) FinancialsPRGOFinancialPerrigo Company PLC

Perrigo Company PLC (PRGO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Self Care, accounting for 63.8% of total sales, equivalent to $576.60M. Other significant revenue streams include Specialty Care and Infant Formula. Understanding this composition is critical for investors evaluating how PRGO navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Perrigo Company PLC maintains a gross margin of 30.69%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 3.80%, while the net margin is 8.65%. These profitability ratios, combined with a Return on Equity (ROE) of -48.75%, provide a clear picture of how effectively PRGO converts its operational activities into shareholder value.

In the context of the broader market, PRGO competes directly with industry leaders such as ZYME and AGIO. With a market capitalization of $2.01B, it holds a significant position in the sector. When comparing efficiency, PRGO's gross margin of 30.69% stands against ZYME's 100.00% and AGIO's 93.30%. Such benchmarking helps identify whether Perrigo Company PLC is trading at a premium or discount relative to its financial performance.

Perrigo's recent financial performance shows a net income of $74.5 million in Q2 2026, a recovery from previous losses, but overall, the company has faced significant challenges with a forward P/E ratio of 6.90, indicating potential undervaluation despite recent struggles.